ALK-Abelló A/S
ALK-Abelló A/S (AKABY) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
akaby · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
ALK-Abelló A/SYou AKABY | — | 45.91x | — | $5.78 |
 Abcam plc ABCZF | $5.1B | N/A | — | $0.00 |
 Alpine Immune Sciences, Inc. ALPN | $4.5B | N/A | — | -$0.64 |
 Arena Pharmaceuticals, Inc. ARNA | $0M | N/A | — | -$11.33 |
 Churchill Capital Corp XI CCXI | $431M | 1495.64x | — | $0.01 |
 Global Blood Therapeutics, Inc. GBT | $0M | N/A | — | -$4.82 |
 IVERIC bio, Inc. ISEE | $5.5B | N/A | — | -$1.45 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for ALK-Abelló A/S (AKABY) measures how much investors pay for each dollar of the company's trailing earnings. AKABY's current PE ratio of 45.91x is calculated by dividing its stock price of $90.00 by its TTM earnings per share of $5.78.
Frequently asked questions
AKABY pe ratio · 6 questionsAKABY's current PE ratio is 45.91x as of 2026-06-09, based on a stock price of $90.00 and TTM EPS of $5.78. Data sourced from Financial Modeling Prep via AKABY's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · ALK-Abelló A/S SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09